Original articleHidradenitis suppurativa (HS): An unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases
Section snippets
Methods
From November 1, 2013, to July 4, 2015, we performed a nationwide retrospective multicenter study, asking dermatologists and rheumatologists to report all cases of HS that occurred for the first time in patients receiving BA for a chronic inflammatory disease. A standardized questionnaire was available on the World Wide Web site of the Club Rheumatisms and Inflammation and the French Society of Dermatology. The diagnosis of HS had to be confirmed by a dermatologist. The study was approved by
Results
From May 2004 to July 2015, in 12 centers we recorded 25 patients who developed HS while receiving BA (20 female, 5 male) (Table I). Two patients had a family history of HS, 52% were smokers, 36% had a body mass index 30 or higher, and 60% had a body mass index 25 or higher. Inflammatory rheumatisms (rheumatoid arthritis, n = 7; ankylosing spondylitis, n = 5; psoriatic arthritis, n = 1; synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome, n = 1; chronic juvenile arthritis,
Discussion
De novo onset of HS after administration of BA for chronic inflammatory diseases has been reported on only 2 occasions.8, 9 We present a series of 25 additional similar cases, suggesting that this condition may be underreported. A search of the national pharmacosurveillance registry yielded no additional case and showed that only 5 of these 25 cases had been reported to the registry.
Our patients shared demographic features with those reported for HS (ie, female predominance, smoking, overweight
References (30)
- et al.
Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial
J Am Acad Dermatol
(2010) - et al.
An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa
J Am Acad Dermatol
(2014) - et al.
Identification of three hidradenitis suppurativa phenotypes: latent class analysis of a cross-sectional study
J Invest Dermatol
(2013) - et al.
Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity
J Am Acad Dermatol
(2009) - et al.
Hidradenitis suppurativa: a retrospective study of 846 Dutch patients to identify factors associated with disease severity
J Am Acad Dermatol
(2014) - et al.
Hidradenitis suppurativa in patients with inflammatory bowel disease: a population-based cohort study in Olmsted County, Minnesota
Clin Gastroenterol Hepatol
(2016) - et al.
Features of patients with Crohn's disease and hidradenitis suppurativa
Clin Gastroenterol Hepatol
(2016) - et al.
Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-alpha inhibitors: the Mayo Clinic experience, 1998 to 2010
J Am Acad Dermatol
(2012) - et al.
Alopecia areata occurring during anti-TNF therapy: a national multicenter prospective study
J Am Acad Dermatol
(2014) - et al.
Development of inflammatory bowel disease during anti-TNF-alpha therapy for inflammatory rheumatic disease: a nationwide series
Joint Bone Spine
(2012)
Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis
Semin Arthritis Rheum
Paradoxical adverse effects of anti-TNF-alpha treatment: onset or exacerbation of cutaneous disorders
Expert Rev Clin Immunol
Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa
J Eur Acad Dermatol Venereol
Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial
Ann Intern Med
A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa
Br J Dermatol
Cited by (54)
Commonly prescribed medications associated with alopecia
2023, Journal of the American Academy of DermatologyReply to: Comment on “Sirolimus as combination rescue therapy with tumor necrosis alpha inhibitors for severe, refractory hidradenitis suppurativa”
2021, Journal of the American Academy of DermatologyApplication of IL-6/IL-6R inhibitors in immunoinflammatory skin diseases
2024, China Journal of Leprosy and Skin DiseasesECCO Guidelines on Extraintestinal Manifestations in Inflammatory Bowel Disease
2024, Journal of Crohn's and Colitis
Funding sources: None.
Disclosure: Authors reported conflicts with AbbVie (APV, VB, JM, DJ), Astellas (VB), Amgen (DJ), BMS (FA, VB, JM), Galderma (FA), Gedeon (VB), Hospira (JM), Janssen (FA, JM, DJ), Leo Pharma (FA), Lilly (DJ), MSD (DJ), Nordic Pharma (JM), Novartis (FA), Pfizer (VB, JM, DJ), Roche (FA, VB, JM, DJ), Sobi (DJ), UCB (JM).